Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The company has proposed a $8.9 billion settlement to end tens of thousands of cases and stop new ones from coming through

Johnson & Johnson Bankruptcy Talk: Q2 Earnings Soar, But Litigation Looms On Horizon

Johnson & Johnson (NYSE:JNJ)'s bid to settle thousands of lawsuits that claimed the company's talcum powder caused cancer is among the largest ever when adjusted for inflation. Having agreed to pay around £6.8bn (US$8.9bn) to settle the cases in April, J&J's proposed pay-out marks the largest since the early 2000s and the eighth highest of all time, according to Arizona-based law firm High Rise Financial.

Johnson & Johnson talcum powder settlement among largest ever

General Mills

PepsiCo

What's one of the best predictors of stock price performance? If you said earnings growth, you're right.

3 Consumer Discretionary Stocks That Still Have Pricing Power

Kenvue

Johnson & Johnson said on Monday it had launched an exchange offer for its investors to exchange J&J's shares with those of its consumer health unit Kenvue.

J&J begins share exchange offer for consumer health spin-off Kenvue

Johnson & Johnson JNJ, +1.07% said Monday it is planning to spin off at least 80.1% of its shares of Kenvue Inc. KVUE, -2.04% through an exchange offer. The consumer goods and healthcare giant announced its intention to launch an exchange offer for the separation of Kenvue, its consumer health business which went public in May, when it reported earnings last week.

Johnson & Johnson to spin off at least 80.1% of Kenvue shares in an exchange offer

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) announced intent to file a Form S-4 Registration Statement today with the Securities and Exchange Commission.

Kenvue To File Form S-4 Registration Statement in Connection with Johnson & Johnson Exchange Offer Announcement

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced its intention to split-off at least 80.1% of the shares of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) through an exchange offer. Kenvue, formerly Johnson & Johnson's Consumer Health business, completed its initial public offering (“IPO”) in May 2023. Through the planned exchange offer, Johnson & Johnson shareholders can exchange all, some or none of their shares of Johnson & Johnson common stock for sha.

Johnson & Johnson Launches Exchange Offer for Separation of Kenvue Inc.

Amgen

Caterpillar

Salesforce

Goldman Sachs

Home Depot

Intel

JPMorgan Chase & Co

UnitedHealth Group

The Dow's 10-straight day rally keeps making history — it hasn't done this since at least 2017. And investors can thank a select group.

11 Stocks Drive The Dow's Amazing 10-Straight Day Rally

First Trust Nasdaq Pharmaceuticals ETF 

Hawaiian Electric Industries

iShares U.S. Healthcare ETF

Vanguard Health Care ETF

Health Care Select Sector SPDR Fund

Johnson & Johnson (JNJ) continued with its long streak of earnings beat. It topped the revenue estimate as well as lifted the full-year outlook.

5 ETFs to Buy on JNJ's Q2 Earnings Strength

SPDR Dow Jones Industrial Average ETF

Since last week, the Dow Jones index has been performing very well. The index jumped more than 150 points yesterday to log its first nine-day rally since 2017, per a CNBC article.

Stocks in Focus on Dow Jones ETF's First 9-Day Run Since 2017

AbbVie

Coca-Cola

Investors seeking income from dividend stocks should carefully consider the yield offered. While the average yield in the S&P 500 is 1.56%, some stocks offer double or even triple that amount.

3 of the Best Dividend Stocks to Buy for Passive Income Growth

J&J owns nearly 90% of Kenvue shares and plans to reduce its stake in the company through an exchange offer that could launch "as early as the coming days."

Johnson & Johnson investors can soon swap their shares for Kenvue stock — here's what you need to know

One of the more interesting moves in today's market comes from recent spinoff Kenvue (NYSE: KVUE ). Currently, shares of KVUE stock are down around 3% in today's session, as the company reported earnings that beat Wall Street estimates by a rather wide margin.

Is Johnson & Johnson Giving Up on Kenvue (KVUE) Stock?

The Dow outpaced other market indexes on Thursday afternoon. Johnson & Johnson announced solid growth in the second quarter of 2023.

These 2 Stocks Just Sent the Dow Jones Soaring

J&J (JNJ) beats estimates for second-quarter earnings and sales. It raises full-year sales and earnings guidance.

J&J (JNJ) Q2 Earnings & Sales Top, '23 View Upped, Stock Jumps

Disney

Dow Jones Industrial Average stocks to watch in the stock market right now.

What Stocks To Buy Today? 2 Dow Jones Industrial Average Stocks To Watch

Johnson & Johnson (NYSE:JNJ ) Q2 2023 Earnings Conference Call July 20, 2023 8:30 AM ET Company Participants Jessica Moore - Vice President of Investor Relations Joaquin Duato - Chairman of the Board and Chief Executive Officer Joe Wolk - Executive Vice President, Chief Financial Officer Erik Haas - Worldwide Vice President of Litigation Conference Call Participants Larry Biegelsen - Wells Fargo Vamil Divan - Guggenheim Securities Joanne Wuensch - Citibank Chris Schott - JPMorgan Trung Huynh - Credit Suisse Terence Flynn - Morgan Stanley Danielle Antalffy - UBS Louise Chen - Cantor Fitzgerald Operator Good morning, and welcome to Johnson & Johnson's Second Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference.

Johnson & Johnson (JNJ) Q2 2023 Earnings Call Transcript

Shares of Johnson & Johnson advanced as the pharmaceutical and medical products firm posted better-than-expected results and raised its guidance on higher demand for its medtech products.

J&J Beats Estimates and Boosts Outlook as Medtech Product Demand Grows

A surprisingly early distribution and a stretched valuation hit J&J's consumer health arm hard.

Johnson & Johnson Rips Off the Kenvue Band-Aid

Johnson & Johnson beat quarterly expectations Thursday, helped by its new cancer drug Carvykti, and JNJ stock surged.

J&J Stock Roars Higher, Retaking Its 200-Day Line As Small Drugs Drive Big Beat

After three years of waiting, Johnson & Johnson NYSE: JNJ shares have returned to trend, a monumental event for the market which presents a potential buying opportunity for income investors.

Johnson & Johnson's Inflection Point: What it Means for Investors

American Airlines

Both J&J and American Airlines put up solid beats on top and bottom lines, while the labor market remains buoyant.

Q2 Beats for J&J, American; Jobless Claims, Philly Fed Lower

Johnson & Johnson (NYSE: JNJ) opened 5.0% up on Thursday after reporting market-beating results for its fiscal second quarter. J&J stock up on strong outlook Investors are cheering the raised guidance as well.

J&J raises full-year outlook: ‘we're in a very strong position'

The healthcare giant posted better-than-expected 2023 Q2 financial results today.

Why Johnson & Johnson Stock Is Rising Today

Target

Dividend stocks often provide an important source of income for retirees. Target and Johnson & Johnson are two top-shelf dividend stocks suitable for risk-averse investors.

News for Johnson & Johnson Stock (JNJ)